Healthcare Watch List: Arena Pharmaceuticals (NASDAQ:ARNA), Abbott Laboratories (NYSE:ABT), UnitedHealth Group (NYSE:UNH), AstraZeneca (NYSE:AZN)

FB Nasdaq FB Facebook

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) reported that Eisai Inc. has launched a national television advertising campaign for BELVIQ® (lorcaserin HCl), an FDA-approved prescription treatment for chronic weight management. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock performance was 0.32% in last session and finished the day at $6.20. Traded volume was 4.92million shares in the last session and the average volume of the stock remained 5.60million shares. The beta of the stock remained -0.41. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) insider ownership is 0.70%.

Abbott Laboratories Inc reported (NYSE:ABT) better-than-expected quarterly earnings on cost controls, but sales came in slightly below Wall Street expectations. The company on April 16 said it earned $375 million, or 24 cents per share in the first quarter. That compared with $544 million, or 34 cents per share, in the year-ago quarter, when Abbott took charges for licensing and acquisitions. Abbott Laboratories (NYSE:ABT) dropped -0.57 percent to $38.71 Monday on volume of 6.92million shares. The intra-day range of the stock was $38.45 to $38.99. Abbott Laboratories (NYSE:ABT) has a market capitalization of $59.73billion.

UnitedHealth Group, Inc. (NYSE:UNH) the nation’s largest health insurer, reported a first-quarter earnings decline Thursday, blaming ObamaCare taxes, Medicare Advantage cuts and Gilead Sciences’ costly hepatitis C drug. UnitedHealth Group Inc. (NYSE:UNH)’s stock on Apr 21, 2014 reported a decrease of -1.10% to the closing price of $74.95. Its fifty two weeks range is $58.03 -$83.32. The total market capitalization recorded $74.14billion. The overall volume in the last trading session was 6.91million shares. In its share capital, UNH has 989.19million outstanding shares.

U.S. shares in AstraZeneca PLC (ADR) (NYSE:AZN) rose Monday on speculation the company had been approached by rival drug maker Pfizer Inc. about takeover talks. On Monday, shares of AstraZeneca plc (ADR) (NYSE:AZN) advanced 8.84% to close the day at $69.10. Company return on investment (ROI) is 9.00% and its monthly performance is recorded as 6.55%. AstraZeneca plc (ADR) (NYSE:AZN) quarterly revenue growth is 11.54%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone